Novartis is discussing the possible acquisition of U.S. generic-drugs maker Amneal Pharmaceuticals, in a bid to boost its Sandoz generics business, says Bloomberg sources.
Sources told Bloomberg that the sale could value NJ-based Amneal at as much as $8 billion. Amneal has 115 approved molecules; among them the antiviral acyclovir to treat herpes, as well as gabapentin for epilepsy and pain.
Novartis' investment in biosimilars is beginning to pay off, with its portfolio of four drugs expected to cross the $1 billion sales threshold in 2016.
Read the Bloomberg coverage